DGIdb - MERCAPTOPURINE Drug Record

MERCAPTOPURINE chembl:CHEMBL1425 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MERCAPTOPURINE ANHYDROUS
MERCAPTOPURINE
6-THIOXOPURINE
MERCAPURIN
6-MP
MERCAPTOPURINUM
PURINETHOL®
6-MERCAPTOPURINE
6-THIOHYPOXANTHINE
MERCAPTOPURINA
6 MP
chembl:CHEMBL1425
drugbank:01033
pubchem.compound:667490
rxcui:1546028
chemidplus:50-44-2

Drug Info:

FDA Approval	1953
Drug Class	small molecule
Drug Indications	Antineoplastic Agents
Drug Class	antineoplastic agents
Year of Approval	1953
Drug Categories	drugs for obstructive airway diseases
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	narrow therapeutic index drugs
Drug Categories	nucleoside metabolic inhibitor
Drug Categories	oat3/slc22a8 inhibitors
Drug Categories	oat3/slc22a8 substrates
Drug Categories	xanthine derivatives

(8 More Sources)

Publications:

Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Kim HS et al., 2017, A coding variant in <i>FTO</i> confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD., Gut
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Sahasranaman et al., 2008, Clinical pharmacology and pharmacogenetics of thiopurines., Eur. J. Clin. Pharmacol.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Dorababu P et al., 2012, Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL., Pharmacogenomics
Brouwer C et al., 2005, Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment., Clin Chim Acta
Meyer JA et al., 2013, Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia., Nat Genet
Tzoneva et al., 2013, Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL., Nat. Med.
Ban H et al., 2010, The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease., J Gastroenterol
Valerie NC et al., 2016, NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine., Cancer Res
Liang DC et al., 2016, NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia., Pharmacogenomics J
Soler AM et al., 2018, TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay., Br J Haematol
Tsujimoto S et al., 2018, Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms., Leukemia
Shih YC et al., 2019, Azathioprine-induced myelosuppression in two pemphigus vulgaris patients with homozygous polymorphism of NUDT15., J Dermatol
Kakuta Y et al., 2018, NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study., J Gastroenterol
Moriyama T et al., 2017, Novel variants in <i>NUDT15</i> and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry., Blood
Ailing Z et al., 2016, Further evidence that a variant of the gene NUDT15 may be an important predictor of azathioprine-induced toxicity in Chinese subjects: a case report., J Clin Pharm Ther
Asada A et al., 2016, NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease., J Gastroenterol
Suzuki H et al., 2016, Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age., J Hum Genet
Moriyama T et al., 2016, NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity., Nat Genet
Cargnin S et al., 2018, Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis., Pharmacol Res
Moriyama T et al., 2017, The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia., Pharmacogenet Genomics
Tanaka Y et al., 2015, Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia., Br J Haematol
Shah SA et al., 2017, Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients., J Gastroenterol Hepatol
Kakuta Y et al., 2016, NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD., Pharmacogenomics J
Zhu X et al., 2016, NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease., Aliment Pharmacol Ther
Lee YJ et al., 2016, NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease., Eur J Gastroenterol Hepatol
Zgheib NK et al., 2017, NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon., Pediatr Blood Cancer
Kishibe M et al., 2018, Severe thiopurine-induced leukocytopenia and hair loss in Japanese patients with defective NUDT15 variant: Retrospective case-control study., J Dermatol
Wong FC et al., 2016, NUDT15 variant and thiopurine-induced leukopenia in Hong Kong., Hong Kong Med J
Heap GA et al., 2014, HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants., Nat Genet
Hareedy MS et al., 2015, Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients., Pharmacogenomics
Stocco G et al., 2009, Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia., Clin Pharmacol Ther
Adam de Beaumais T et al., 2011, Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy., Br J Clin Pharmacol
Sugita et al., 1992, [Analysis of lymphocyte surface markers in childhood acute lymphoblastic leukemia during maintenance chemotherapy]., Gan To Kagaku Ryoho
Smid A et al., 2016, PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy., Sci Rep
López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
Gaulton et al., 2012, ChEMBL: a large-scale bioactivity database for drug discovery., Nucleic Acids Res.
Dubinsky, 2004, Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety., Clin. Gastroenterol. Hepatol.
Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
Eldem İ et al., 2018, SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy., J Pediatr Hematol Oncol
Stocco G et al., 2012, PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity., Hum Mol Genet
Li B et al., 2015, Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL., Nat Med

MERCAPTOPURINE NUDT15

Interaction Score: 13.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27530327 26503813 28146264 27558924 29967377 30035323 29923122 28659275 27381176 26590936 27193222 26878724 30048756 28445187 26033531 27416873 26076924 27604507 26735160 27577869 30101994 27095468

Sources:
FDA PharmGKB CIViC
MERCAPTOPURINE PACSIN2

Interaction Score: 2.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22846425 27452984

Sources:
PharmGKB
MERCAPTOPURINE HPRT1

Interaction Score: 2.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
15354273

Sources:
TEND TdgClinicalTrial DrugBank
MERCAPTOPURINE ITPA

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26237184 18685564 21395650

Sources:
PharmGKB
MERCAPTOPURINE NT5C2

Interaction Score: 1.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15990089 23377183 23377281

Sources:
PharmGKB CIViC
MERCAPTOPURINE PRPS1

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25962120

Sources:
CIViC
MERCAPTOPURINE PPAT

Interaction Score: 1.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
21948594 18506437

Sources:
TTD DrugBank
MERCAPTOPURINE HLA-DQA1

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25217962

Sources:
PharmGKB
MERCAPTOPURINE GNMT

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27452984

Sources:
PharmGKB
MERCAPTOPURINE IMPDH1

Interaction Score: 0.53

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11752352 18506437

Sources:
TTD DrugBank
MERCAPTOPURINE FTO

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27558924

Sources:
PharmGKB
MERCAPTOPURINE DROSHA

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24614921

Sources:
PharmGKB
MERCAPTOPURINE TPMT

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration TPMT:A80P,Y240C,A154T,A167G

Alteration TPMT:.

Drug family Purine analog

PMIDs:
None found

Sources:
FDA CGI
MERCAPTOPURINE FOLH1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22838948

Sources:
PharmGKB
MERCAPTOPURINE GATA3

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24141364

Sources:
PharmGKB
MERCAPTOPURINE NOTCH1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Mercaptopurine

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB
MERCAPTOPURINE RB1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Mercaptopurine

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB
MERCAPTOPURINE TYMSOS

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MERCAPTOPURINE IL2RA

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1580639

Sources:
NCI
MERCAPTOPURINE ABCC4

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20393862

Sources:
PharmGKB
MERCAPTOPURINE HLA-DRB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25217962

Sources:
PharmGKB
MERCAPTOPURINE SLCO1B1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29683944

Sources:
PharmGKB
MERCAPTOPURINE HBB

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE TDP1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MERCAPTOPURINE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MERCAPTOPURINE KDM4E

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MERCAPTOPURINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MERCAPTOPURINE BAZ2B

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE TP53

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE IDH1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE ALDH1A1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE KDM4A

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MERCAPTOPURINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MERCAPTOPURINE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB01033

Version: 5.1.7

Alternate Names:

50-44-2 CAS Number

Leukerin Drug Brand

Mercaptopurine Tablets USP Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories antimetabolites

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

Sahasranaman et al., 2008, Clinical pharmacology and pharmacogenetics of thiopurines., Eur. J. Clin. Pharmacol.

Dubinsky, 2004, Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety., Clin. Gastroenterol. Hepatol.

TdgClinicalTrial: MERCAPTOPURINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1953

Publications:
TEND: MERCAPTOPURINE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Year of Approval 1953

Drug Class antineoplastic agents

Publications:
DTC: MERCAPTOPURINE
- Version: 02-September-2020
Alternate Names:

CHEMBL1425 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
NCI: 6-MP
- Version: 14-September-2017
Alternate Names:

C195 NCI drug code

Drug Info:

Publications:

Sugita et al., 1992, [Analysis of lymphocyte surface markers in childhood acute lymphoblastic leukemia during maintenance chemotherapy]., Gan To Kagaku Ryoho
JAX-CKB: Mercaptopurine
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

PharmGKB: mercaptopurine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet

Kim HS et al., 2017, A coding variant in <i>FTO</i> confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD., Gut

Dorababu P et al., 2012, Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL., Pharmacogenomics

CIViC: MERCAPTOPURINE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Meyer JA et al., 2013, Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia., Nat Genet

Tzoneva et al., 2013, Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL., Nat. Med.

Moriyama T et al., 2016, NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity., Nat Genet

TTD: Mercaptopurine
- Version: 2020.06.01
Alternate Names:

D09UZO TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1425
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Mercaptopurine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
CGI: Mercaptopurine
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Alteration	TPMT:A80P,Y240C,A154T,A167G
Alteration	TPMT:.
Drug family	Purine analog

combination therapy	Ribociclib + Mercaptopurine
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	decreased response

50-44-2	CAS Number
Leukerin	Drug Brand
Mercaptopurine Tablets USP	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	antimetabolites

Trial Name	-
Novel drug target	Established target

MERCAPTOPURINE Drug Record

MERCAPTOPURINE chembl:CHEMBL1425 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27530327 26503813 28146264 27558924 29967377 30035323 29923122 28659275 27381176 26590936 27193222 26878724 30048756 28445187 26033531 27416873 26076924 27604507 26735160 27577869 30101994 27095468

Sources: FDA PharmGKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22846425 27452984

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 15354273

Sources: TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26237184 18685564 21395650

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15990089 23377183 23377281

Sources: PharmGKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25962120

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 21948594 18506437

Sources: TTD DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25217962

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27452984

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 11752352 18506437

Sources: TTD DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27558924

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24614921

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Alteration TPMT:A80P,Y240C,A154T,A167G Alteration TPMT:. Drug family Purine analog

PMIDs: None found

Sources: FDA CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22838948

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24141364

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Mercaptopurine Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type decreased response

PMIDs: 28151717

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Mercaptopurine Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type decreased response

PMIDs: 28151717

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1580639

Interaction Types & Directionality:

n/a

PMIDs:
27530327 26503813 28146264 27558924 29967377 30035323 29923122 28659275 27381176 26590936 27193222 26878724 30048756 28445187 26033531 27416873 26076924 27604507 26735160 27577869 30101994 27095468

Sources:
FDA PharmGKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22846425 27452984

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
15354273

Sources:
TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
26237184 18685564 21395650

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15990089 23377183 23377281

Sources:
PharmGKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
25962120

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
21948594 18506437

Sources:
TTD DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
25217962

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27452984

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
11752352 18506437

Sources:
TTD DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
27558924

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24614921

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration TPMT:A80P,Y240C,A154T,A167G

Alteration TPMT:.

Drug family Purine analog

PMIDs:
None found

Sources:
FDA CGI

Interaction Types & Directionality:

n/a

PMIDs:
22838948

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24141364

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Mercaptopurine

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Mercaptopurine

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
1580639

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
20393862

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25217962

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29683944

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a